Bristol-Myers Squibb Company BMY
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Bristol-Myers Squibb Company is a large-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $124.9B, based in the USA.
It employs about 32,500 people and has been listed since Jan 01, 1972.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM.
Cheap or expensive? relatively cheap
Its price-to-earnings (P/E) is 13.5 versus 31.6 for the median of the Healthcare sector in our universe (22 companies) — relatively cheap.
Revenue is growing 6% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 9.4 — they expect higher earnings.
The average analyst price target is 66.71, 9% above the current price (their view, not ours).
The stock sits at 75% of its one-year range (0% = the low, 100% = the high).
The risks
- • Net debt is 1.4× shareholders' equity — high leverage.
Strengths
- ✅ Profitable — 26 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Most analysts rate it buy (10 vs 1).
- ✅ Pays a dividend (4.1% a year).
What changed this week
Over the past week the stock fell 1.7% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy? finance.yahoo.com · 2026-10-04
- AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot seekingalpha.com · 2026-10-03
- Agios' Growth Story Hinges on Mitapivat's Commercial Expansion finance.yahoo.com · 2026-10-02
- Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio? finance.yahoo.com · 2026-10-02
- Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement finance.yahoo.com · 2026-10-01
- U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients* finance.yahoo.com · 2026-09-30
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.